CTI to Report Results from STELLAR 3 Pivotal Trial of Xyotax Early

Cell Therapeutics expects results to be available from its pivotal trial of Xyotax in non-small cell lung cancer (NSCLC), known as STELLAR 3, in early- to mid-March.

CTI had previously reported that it expected results from the STELLAR 3 trial in late March or early April.

"The clinical research organization (CRO) has recently notified CTI that they may have the database clean and ready earlier than expected," stated Scott Stromatt, senior vice president for clinical and regulatory development at CTI. "Based on this revised timeline, we expect to be in a position to have the results for submission of a late breaking abstract ahead of the ASCO deadline."

The STELLAR trials are the largest randomized trials to date in either second-line non-small cell lung (NSCL) cancer or front-line PS2 NSCL cancer patients.